S-1: Helius Medical Technologies Announces Best Efforts Public Offering to Bolster Operations

Helius Medical Technologies is undertaking a best efforts public offering of common stock, warrants, and pre-funded warrants to raise capital for operations and working capital.

Summary

• Helius Medical Technologies has filed a registration statement for a proposed best efforts public offering.
• The offering includes shares of Class A common stock, Series A warrants, Series B warrants, and pre-funded warrants.
• Each share of common stock is offered with one Series A warrant and one Series B warrant.
• The assumed combined public offering price is $ per share.
• Series A warrants are exercisable for five years at 110% of the offering price.
• Series B warrants are exercisable for twelve months at 110% of the offering price and are redeemable by the company under certain conditions.
• Pre-funded warrants are offered to purchasers who would otherwise exceed beneficial ownership limits.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol HSDT.
• Craig-Hallum Capital Group LLC is acting as the exclusive placement agent.
• The company intends to use the net proceeds for funding operations, working capital, and general corporate purposes.
• The company received a Nasdaq deficiency notice on April 4, 2024, for not meeting the minimum stockholders' equity requirement.
• The company expects revenue for the quarter ended March 31, 2024, to be approximately $135,000, compared to $111,000 for the quarter ended March 31, 2023.
• The loss from operations for the quarter ended March 31, 2024, is expected to range from $3.4 million to $3.6 million, compared to $3.8 million for the quarter ended March 31, 2023.
• Cash and cash equivalents totaled approximately $3.6 million as of March 31, 2024, compared to $5.2 million as of December 31, 2023.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the Nasdaq deficiency notice, ongoing losses, and the need for additional capital. However, there are some positive signs, such as increased revenue and decreased loss from operations in Q1 2024 compared to Q1 2023.

Positives

• The company has partnered with Lovell Government Services to expand the availability of the PoNS device.
• Revenue for Q1 2024 is expected to increase compared to Q1 2023 ($135,000 vs $111,000).
• Loss from operations for Q1 2024 is expected to decrease compared to Q1 2023 ($3.4-3.6 million vs $3.8 million).
• The company had no debt obligations outstanding at March 31, 2024.

Negatives

• The company received a Nasdaq deficiency notice for not meeting the minimum stockholders' equity requirement.
• The company has a history of losses and may not achieve or sustain profitability in the future.
• The company's cash and cash equivalents decreased from $5.2 million as of December 31, 2023, to $3.6 million as of March 31, 2024.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• The market price of the company's common stock may be highly volatile.
• The company is not in compliance with Nasdaq's continued listing requirements.
• The company has not paid and does not intend to pay dividends on its common stock.
• The company's inability to protect its confidential information and trade secrets would harm its business and competitive position.
• The company's failure to comply with healthcare laws could result in substantial penalties and financial exposure.
• The company is reliant on third-party, single-sourced contract manufacturing, exposing it to risks that could delay sales or result in higher costs or lost product revenues.

Future Outlook

The company intends to use the net proceeds from this offering for funding operations, working capital, and general corporate purposes, and may use a portion for acquisitions of complementary businesses, products, technologies, or licenses.

Industry Context

Helius Medical Technologies operates in the neurotechnology industry, focusing on non-implantable technologies for neurological wellness. The company's PoNS device competes with other neuromodulation therapies and devices targeting gait and balance deficits. The market is characterized by ongoing research, clinical trials, and regulatory approvals to demonstrate the safety and efficacy of these technologies.

Comparison to Industry Standards

• It is difficult to compare Helius directly to industry standards due to its unique product and focus.
• Companies like NeuroMetrix and Boston Scientific also operate in the neuromodulation space, but with different product offerings and target markets.
• NeuroMetrix focuses on wearable neurostimulation devices for pain management, while Boston Scientific has a broader portfolio of implantable and non-implantable neuromodulation devices.
• Given the preliminary revenue of $135,000 for Q1 2024, Helius's revenue is significantly lower than larger, more established players in the neuromodulation market.
• However, Helius is focused on a specific niche (gait and balance deficits) and is in an earlier stage of commercialization compared to these companies.

Stakeholder Impact

• Shareholders may experience dilution due to the public offering.
• Employees' job security could be affected by the company's financial performance.
• Customers may benefit from increased availability of the PoNS device.
• Suppliers and creditors may be affected by the company's ability to meet its financial obligations.

Next Steps

• The company intends to submit a plan to Nasdaq to regain compliance with listing rules by May 20, 2024.
• The company will proceed with the best efforts public offering.
• The company will continue to pursue commercialization of the PoNS device in the U.S. and Canada.
• The company will continue to seek regulatory approvals and expand its market awareness.

Key Dates

Keywords

public offering, Helius Medical Technologies, PoNS device, warrants, common stock, neuromodulation, capital raise, Nasdaq, Lovell Government Services, stockholders equity